The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CorMedix (CRMD) drew fresh attention after reporting robust Q1 2026 results, with DefenCath playing a central role in revenue ...
CRMD's DefenCath is an FDA-approved catheter lock solution reducing CRBSIs in chronic hemodialysis patients. CRMD saw higher-than-expected outpatient dialysis utilization of DefenCath, likely lifting ...
CorMedix’s CRMD lead drug, DefenCath (Taurolidine + Heparin), is currently its only marketed product that generates revenues for the company. The FDA approved CorMedix’s DefenCath in late 2023 as the ...
CorMedix's Q4 revenues likely to be driven by strong DefenCath sales uptake in outpatient dialysis settings. CRMD's Melinta acquisition expanded its portfolio, recording incremental sales from seven ...
Hosted on MSN
CorMedix Lifts Q2 Outlook As Dialysis Partner Expands DefenCath Use; Needham Raises PT To $20
CorMedix raised its second-quarter sales forecast on Monday after disclosing that its large dialysis organization (LDO) partner has started implementing DefenCath with a broader reach than previously ...
BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...
Hosted on MSN
CorMedix Stock Breaks Out To 2-Month High: Analysts Reset Price Targets After Blowout Q3 And Surging DefenCath Demand
・Analysts delivered mixed revisions following the earnings release, with one maintaining its valuation outlook and another lowering its target after reviewing updated guidance. ・The company ...
CorMedix’s CRMD lead therapy, DefenCath (taurolidine + heparin), is currently the company’s majority revenue driver. The FDA approved DefenCath in late 2023 as the first and only antimicrobial ...
CorMedix Inc. (NASDAQ:CRMD) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents. Sales reached $104.27 million, a jump from $11.5 million a year ago, ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. It may be unusual to see nearly a 10% gain from a single ...
The majority of CorMedix’s CRMD revenues come from its lead product, DefenCath, which is approved as the first and only antimicrobial catheter lock solution in the United States. The product is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results